^
Association details:
| Biomarker: | CD22 positive |
|---|---|
| Cancer: | Lymphoma |
| Drug: | Lumoxiti (moxetumomab pasudotox) (Protein synthesis inhibitor, CD22-targeted cytotoxin) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
Excerpt:
...- Evidence of CD22-positive malignancy by one of the following criteria:...
Trial ID:
Source:
Title:
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
Excerpt:
...- CD22 positive according to at least 1 of the following criteria:...
Trial ID:
Less C2 evidence
Source:
Title:
Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments
Published date:
10/28/2021
Excerpt:
The human CD22-targeted immunotoxin Moxetumomab was highly active against h/mCD22+ lymphoma and similarly reduced infiltration of bone marrow and spleen of all three models up to 90-fold while efficacy against lymphoma in lymph nodes varied substantially, highlighting relevance of organ-specific TME....The combination of anti-PD-L1 and Moxetumomab significantly prolonged survival to a median of 28.5 days compared to Moxetumomab alone (p = 0.0380).
DOI:
10.3390/ijms221910433
Source:
Title:
Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments
Published date:
09/28/2021
Excerpt:
The human CD22-targeted immunotoxin Moxetumomab was highly active against h/mCD22+ lymphoma and similarly reduced infiltration of bone marrow and spleen of all three models up to 90-fold while efficacy against lymphoma in lymph nodes varied substantially, highlighting relevance of organ-specific TME....The combination of anti-PD-L1 and Moxetumomab significantly prolonged survival to a median of 28.5 days compared to Moxetumomab alone (p = 0.0380).
DOI:
10.3390/ijms221910433
